Skip to main content

Page last checked

Comparison · sourced side by side

Retatrutide vs Tirzepatide

The sources here do not include a direct trial of retatrutide against tirzepatide. Each drug was tested in its own study, with different people and follow-up times. The gap between those results does not show how the drugs compare. Read each study’s doses, results and limits below.

Human trial FDA label

What matters first

Head-to-head evidence
No direct trial
Retatrutide record
Human trial; 1 sourced dose row
Tirzepatide record
FDA label; 2 sourced dose rows

Is there a head-to-head trial?

The cited trials do not compare retatrutide and tirzepatide head to head. One study may enroll people who weigh more at the start or follow them for longer. Those differences can affect the results. Subtracting one study’s weight-loss figure from another’s does not tell us how much of the gap comes from the drug.

Each result can still be read on its own. Both appear below with their own citations, but not on one shared chart.

RetatrutideHuman trial

48-week phase 2 dose-finding trial · 338 participants · 48 weeks

  • 1 mg — -8.7% mean weight change
  • 4 mg — -17.1% mean weight change
  • 8 mg — -22.8% mean weight change
  • 12 mg — -24.2% mean weight change
  • placebo — -2.1%

At 48 weeks, the groups lost 8.7% of their starting weight at 1 mg and 24.2% at 12 mg, on average. The 4 mg and 8 mg groups lost 17.1% and 22.8%. The placebo group lost 2.1%.

The full retatrutide record →
TirzepatideFDA label

Approved with a prescribing label; its dosing schedule and reaction profile are label-sourced and shown in the table below.

The full tirzepatide record →

Side by side

Compare approved uses, studied doses and reported effects. Missing information is labeled, and the sources for the clinical figures appear below.

Retatrutide and Tirzepatide side by side: drug class, brand names, FDA approval, strongest source, dosing, half-life, boxed warning, reported reactions and typical vial sizes
PropertyRetatrutideTirzepatide
Drug classGIP/GLP-1/glucagon triple receptor agonist (investigational)GIP/GLP-1 dual receptor agonist
Brand namesNone — no approved productZepbound, Mounjaro
FDA approvalNot approved — investigationalApproved
Strongest sourceHuman trialFDA label
Dosing1–12 mg once weekly5–15 mg once weekly (5, 10, or 15 mg)
Half-lifeNot recorded≈ 5 days
Boxed warningNone on recordRisk of thyroid C-cell tumors
Reactions on record615
Typical vial sizes10 mg · 20 mg · 30 mg5 mg · 10 mg · 15 mg · 30 mg · 60 mg

Every clinical value above is cited in the Sources list. Reference information, not a recommendation.

4Comparison detailsMechanism, side effects, regulatory context, and source records

How they work differently

Retatrutide is a gip/glp-1/glucagon triple receptor agonist. Tirzepatide is a gip/glp-1 dual receptor agonist. They switch on different signals in the body. That can change both benefits and side effects. Even with a shared target, one drug cannot simply take the place of the other.

More targets do not guarantee a better result. They change both the effect and the side-effect pattern. A clinician weighs those tradeoffs for each person.

Side effects compared

Side effects below come from each compound’s own page, grouped by whether both records list them. A side effect on one list only means the other record does not carry it — not that it never happens.

On both records
  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Decreased appetite
Recorded for Retatrutide only
  • Increased heart rate
Recorded for Tirzepatide only
  • Abdominal pain
  • Dyspepsia (indigestion)
  • reactions where injected
  • Fatigue
  • Acute pancreatitis
  • Gallbladder disease (cholelithiasis)
  • Hypoglycemia (with insulin or a sulfonylurea)
  • Acute kidney injury (from dehydration)
  • Diabetic retinopathy complications
  • Severe hypersensitivity reactions
Full retatrutide side-effect record

Frequencies, serious reactions and the source for each.

Full tirzepatide side-effect record

Frequencies, serious reactions and the source for each.

Regulatory status compared

Retatrutide

FDA has not approved retatrutide.

It is still in trials and has no dosing label. Any product sold today is unapproved. The doses here describe study groups, not advice.

Tirzepatide

FDA-approved as branded pens.

Compounded tirzepatide now faces tight limits. FDA declared the shortage over in late 2024. It has proposed dropping tirzepatide from the 503B bulks list.

That leaves one narrow lane: 503A compounding for a named patient with a documented clinical need.

The full regulatory tracker →

Keep reading

Open the individual drug guides for full dose schedules, study details and related tools.

What the sources say about tirzepatide, beyond Retatrutide vs tirzepatide

15 sourced tirzepatide reactions, on its own page, separate from Retatrutide vs tirzepatide.

The retatrutide page behind Retatrutide vs tirzepatide

Retatrutide has published human trial data, separate from Retatrutide vs tirzepatide.

The retatrutide calculator behind Retatrutide vs tirzepatide

The retatrutide vial presets are 1 mL and 2 mL of water. They belong to this tool, not to the Retatrutide vs tirzepatide page.

Convert a tirzepatide amount to units, beyond Retatrutide vs tirzepatide

U-100, U-50 and U-40 barrels for tirzepatide, computed independently of Retatrutide vs tirzepatide.

Every tirzepatide step, outside Retatrutide vs tirzepatide

2 sourced tirzepatide values, each traceable without going via Retatrutide vs tirzepatide.

The retatrutide schedule that Retatrutide vs tirzepatide summarizes

The whole retatrutide trial program, in full past Retatrutide vs tirzepatide.

The draw arithmetic behind Retatrutide vs tirzepatide

Vial strength and water volume in and the exact mark out, with Retatrutide vs tirzepatide as context

Where both drugs in Retatrutide vs tirzepatide stand with the regulator

Approval status, proceedings and the date attached to each, with Retatrutide vs tirzepatide as one example

Other ways to compare the options in Retatrutide vs tirzepatide

For more context on Retatrutide vs tirzepatide, check which options have been studied against each other.

The sourcing rules that shape Retatrutide vs tirzepatide

Why a label band and a trial percentage are never averaged, with Retatrutide vs tirzepatide as context

Common questions

Which is more effective, retatrutide or tirzepatide?

The cited studies do not answer that directly. Each drug was studied separately, so subtracting their results does not show how they would compare in the same trial.

Can these two be compared using their separate trial results?

Not reliably. The people, time span and goals can differ from trial to trial. A head-to-head trial tests both drugs in the same study.

Are the side-effect profiles the same?

Both records list 5 of the same side effects, mostly gut symptoms. Their full lists and study groups differ, so matching names do not mean matching rates.

Is either one approved by the FDA?

Tirzepatide is FDA-approved and has a prescribing label. Retatrutide is still experimental, has no approved label, and anything sold today is unapproved.

Does a newer compound mean a better one?

No. A newer drug often has less evidence, a shorter safety record, and no approved label. The strength of the evidence above is more useful than age alone.

Can someone switch between them?

A prescriber needs to consider the reason for treatment, current dose and response before planning a change.

2primary sources, each with the day we read it — open the documents used on this page